NCT03062176 (E-HART) is a Phase 2 clinical trial of Anakinra in Heart Failure, Systolic, sponsored by Virginia Commonwealth University.

Who is sponsoring NCT03062176?

NCT03062176 is sponsored by Virginia Commonwealth University.

What drugs are being tested in NCT03062176?

Interventions in NCT03062176: Anakinra.

What condition does NCT03062176 study?

NCT03062176 studies Heart Failure, Systolic, Renal Disease, End Stage, Chronic Kidney Diseases.

Is NCT03062176 still recruiting?

NCT03062176 is currently withdrawn. Last updated 17 May 2019.

Last reviewed 2019-05-17 · How we verify

NCT03062176: E-HART

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Interleukin-1 Blockade for the Treatment of Heart Failure in Patients With Advanced Chronic Kidney Disease

Withdrawn Phase 2 Last updated 17 May 2019

What this trial tests

Phase 2 trial testing Anakinra in Heart Failure, Systolic. Withdrawn.

Timeline

3 April 2017

Primary endpoint
15 May 2019

15 May 2019

Quick facts

Lead sponsor	Virginia Commonwealth University
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Start date	3 April 2017
Primary completion	15 May 2019
Estimated completion	15 May 2019

Drugs / interventions tested

Anakinra (ANAKINRA) — full drug profile →

Conditions studied

Heart Failure, Systolic — all drugs for Heart Failure, Systolic →
Renal Disease, End Stage — all drugs for Renal Disease, End Stage →
Chronic Kidney Diseases — all drugs for Chronic Kidney Diseases →

Sponsor

Virginia Commonwealth University

Who can join

18 and older, any sex, with Heart Failure, Systolic or Renal Disease, End Stage. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Interleukin-1 blockade for the treatment of heart failure in patients with advanced chronic kidney disease (End-stage renal disease and Heart fAilure - Anakinra Remodeling Trial) is a Phase 2, single-arm trial designed to estimate the effect of anakinra, a recombinant human Interleukin-1 (IL-1) receptor antagonist, on cardiorespiratory fitness in patients with advanced chronic kidney disease and heart failure.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Obstructive nephropathy and molecular pathophysiology of renal interstitial fibrosis.
Nørregaard R, Mutsaers HAM, Frøkiær J, Kwon TH. · · 2023 · cited 75× · PMID 37440209 · DOI 10.1152/physrev.00027.2022

Verify or expand the search:

Other trials of Anakinra

Trials testing the same drug.

NCT06381661 — Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Tra · Phase 2 · not yet recruiting
NCT07281027 — COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE" · Phase 3 · not yet recruiting
NCT07191444 — A Study of Firsekibart Versus Anakinra in Adult-Onset Still's Disease · recruiting
NCT06666335 — A Study to Evaluate Efficacy and Safety of Anakinra in Chinese Patients With Colchicine-resistent FMF · Phase 4 · not yet recruiting
NCT06697431 — Non Inferiority KawasakI Trial With Anakinra · Phase 4 · not yet recruiting

Other recruiting trials for Heart Failure, Systolic

Currently open trials in the same condition.

NCT07199088 — Comparative Efficacy and Safety of Acetazolamide Versus Metolazone as an Adjunct to Standard Therapy in Patients With Ac · NA · recruiting
NCT06336746 — Cardiac Performance During Steep Trendelenburg Position in Patients Undergoing Robotic Surgery Surgery. · recruiting
NCT06675552 — Non-interventional Study on Guideline Directed Medical Therapy for Patients With Heart Failure (HF) in Germany · recruiting
NCT06332391 — Paced Heart Rate Acceleration for Cardiac Conditioning · NA · recruiting
NCT05632432 — Atrial Appendage Micrograft Transplants to Assist Heart Repair After Cardiac Surgery · NA · recruiting

Other Virginia Commonwealth University trials

Trials by the same sponsor.

NCT05936931 — Young Adult-Mediated Intervention to Increase Colorectal Cancer Screening · NA · not yet recruiting
NCT07365839 — Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma · Phase 1 · not yet recruiting
NCT07178158 — Enhancing Addiction Treatment Through Psychoeducation · NA · not yet recruiting
NCT07531316 — Safety and Tolerability Study of VVZ-2471 in Healthy Volunteers · Phase 1 · not yet recruiting
NCT07426913 — Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03062176 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Virginia Commonwealth University
Last refreshed: 17 May 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03062176.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing